Box III Text of the abstract

Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody, and replacing one or more amino acid residues with cysteine. The cysteine engineered antibodies (Ab) may be covalently attached to one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I:Ab-(L-D)$_p$, where p is 1 to 4. Therapeutic uses of the cysteine engineered antibody-drug conjugates are also disclosed herein.